Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

The War and Treaty singer Michael Trotter Jr. tells PEOPLE ahead of the 'Opry 100: A Live Celebration' in Nashville on March ...

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Earlier this year, when US President Donald Trump offered to buy Greenland from Denmark, online rumours circulated that the Danish government might encourage Novo Nordisk, the Danish company behind ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Following in the footsteps of blockbuster drugs such as Ozempic and Wegovy—both powered by semaglutide—Mounjaro (approved for ...